rUTIs

Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
Endpoints
Tue, 11/10/20 - 11:02 am
Locus Biosciences
CARB-X
CRISPR
rUTIs
UTIs
bacteriophage
EIP Pharma
Vertex Pharmaceuticals
dementia
clinical trials